ABD Serotec has demonstrated significant progress using the HuCAL-based technology platform to generate custom-made monoclonal antibodies for research and diagnostic use.
Over the last four years, ABD Serotec gradually improved success rates year on year, starting at 80 per cent in 2006 to reach 98 per cent in 2009.
This was mainly achieved through a high degree of automation in many aspects of the antibody-generation process, by optimising protocols and finally by the implementation of HuCAL Platinum, the latest and most powerful version of Morphosys's antibody libraries.
